Elon Musk's xAI company receives 28 trillion KRW investment... The generative AI boom reignites

The 2026 venture capital market is kicking off at a breathtaking pace. Notably, Elon Musk’s generative AI startup xAI has made a splash by raising up to $20 billion in a single round of funding (approximately 28.8 trillion KRW), becoming the absolute focus. Analysis indicates that within just one week, large investments exceeding $100 million have been continuously pouring in, and following 2025, a new wave of investment has officially begun.

xAI, known for its AI chatbot “Grok,” successfully completed its Series E funding round amid rapid attention from strategic and financial investors since its founding in 2023. This round brings xAI’s total funding to $4.27 billion (approximately 61.4 trillion KRW), and it is actively shaking up the global tech investment landscape.

Subsequent large-scale funding cases are equally impressive. Parabilis Medicines, which develops cancer treatment peptide platforms, secured $305 million (about 439.2 billion KRW) in a Series F round led by RA Capital, Fidelity, and Janus Henderson. Soley Therapeutics, focused on building a cell stress detection platform, received $200 million (around 288 billion KRW) in California, led by Surveyor Capital.

AI model evaluation platform LMArena also successfully raised $150 million (approximately 216 billion KRW), boosting its post-money valuation to $1.7 billion. Additionally, EpiBiologics, which develops extracellular protein degradation technology, and Lyte, focused on robotics and AI perception technology, both ranked among the top with funding amounts of $107 million (about 153.8 billion KRW).

California-based Cambium, developing advanced materials for defense and aerospace, and Rakuten Medical, researching cancer photoimmunotherapy, each raised $100 million (around 144 billion KRW) in Series B and F rounds, respectively. Pomelo Care, providing personalized virtual healthcare services for women and children, also raised $92 million (about 132 billion KRW) in Series C, ranking among the top.

Experts believe that the trend of large-scale deals driven by the AI boom of 2025 has continued into early 2026. Particularly, the massive funding of xAI confirms that the competition for the next-generation generative AI remains fiercely intense. Meanwhile, traditional biotech and healthcare investments exceeding $100 million continue to perform steadily, indicating that risk capital is flowing into the two major pillars of tech startups.

Although xAI holds an overwhelming advantage in funding scale, the diversification of investment targets and the increasing technical difficulty across fields are interpreted as signals that the startup ecosystem as a whole is entering a “qualitative leap” phase. Whether 2026 will become another growth year driven by technological innovation and capital integration is now the focus of investors’ attention.